Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.

Cancer Rep (Hoboken) · 2021 · PMC8388177 · PMID 33934557

Europe PMC DOI

hedged sentence

0.0450

closest p · 0.9× alpha

0.0450

boldest claim

The sentences

modestly significantP = .045actually significant

For men age 60 to 64, even though PSA testing decreased from 2011 to 2013 (APC, −3.2%; P = .054), testing rate showed a modestly significant upward trend from 2013 to 2017 (APC, +1.2%; P = .045).

also in 257 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.